Perry Karsen brings decades of successful executive leadership and board experience to his role as Chairman of the Board of Intellia, a position he assumed in April 2016. He has served in senior executive positions in multi-national biopharmaceutical companies, has led start-up biotechnology companies, and is a member of the board of directors for both public and private biopharmaceutical companies. He also has been a board member and a member of the Executive Committee of the Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine (ARM).
Perry served as the Chief Executive Officer of the Celgene Cellular Therapeutics division (CCT) of Celgene Corporation, a global biopharmaceutical company. Prior to being named CEO of CCT, he served for nearly a decade in other senior executive positions at the company, as Chief Operations Officer and Executive Vice President, and before that as Senior Vice President and Head of Worldwide Business Development. Perry was also President and Chief Executive Officer of Pearl Therapeutics, Inc., a privately held biotechnology company subsequently acquired by AstraZeneca plc.
Perry has held executive positions at Human Genome Sciences, Inc., a biopharmaceutical company subsequently acquired by GlaxoSmithKline; Bristol-Myers Squibb Co; Genentech, Inc., a member of the Roche Group; and Abbott Laboratories. He previously served as a general partner at Pequot Ventures, a venture capital firm.
Perry currently serves as Chairman of the Board of Directors for both OncoMed Pharmaceuticals and Jounce Therapeutics, and serves as a board member for Voyager Therapeutics. He also is a member of the Gladstone Foundation Board and the Sonoma Land Trust Board of Directors.
Perry earned a masters of management degree from Northwestern University’s Kellogg Graduate School of Management, and holds an M.A. in the teaching of biology from Duke University and a B.S. in biological sciences from the University of Illinois, Urbana-Champaign.